5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Medica (Italy) · Vita-Salute San Raffaele University · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
866
total citations
- FWCI
- 37.26
- Percentile
- 100%
- References
- 21
Citations per year
Authors
20- LGLuca GianniCorresponding
Medica (Italy), Vita-Salute San Raffaele University
- TPTadeusz Pieńkowski
Postgraduate School of Molecular Medicine
- YIYoung‐Hyuck Im
Samsung Medical Center
- LTLing‐Ming Tseng
National Yang Ming Chiao Tung University, Taipei Veterans General Hospital
- MLMei-Ching Liu
Koo Foundation Sun Yat-Sen Cancer Center
Topics & keywords
Topics
Keywords
- Pertuzumab
- Docetaxel
- Medicine
- Trastuzumab
- Clinical endpoint
- Epirubicin
- Internal medicine
- Breast cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.